Literature DB >> 8831610

Elevated cyclooxygenase-2 levels in Min mouse adenomas.

C S Williams1, C Luongo, A Radhika, T Zhang, L W Lamps, L B Nanney, R D Beauchamp, R N DuBois.   

Abstract

BACKGROUND & AIMS: Mutations in the APC gene result in an increased propensity to develop intestinal neoplasia; however, a complete understanding of the mechanisms resulting in tumor formation has remained elusive. Min mice possess a mutation in the APC gene and display a neoplastic phenotype similar to that observed in familial adenomatous polyposis coli in humans. Cyclooxygenase (COX) inhibitors decrease tumor multiplicity in the Min mouse intestine. The present study was designed to determine if there was an increase in COX-2 in adenomas harvested from Min mouse intestine.
METHODS: COX-2 messenger RNA levels were determined by Northern blots and reverse-transcription polymerase chain reactions of B6Min x 129 mouse-derived tumors. Protein levels and localization were determined by Western blots and immunohistochemical staining.
RESULTS: The Northern blots revealed an approximately threefold increase in the level of COX-2 messenger RNA in Min mouse adenoma compared with normal mucosa. COX-2 protein levels in adenomatous tissues were also approximately threefold higher compared with normal mucosa from the same mouse. Immunohistochemical staining with a monospecific COX-2 antibody confirmed that increases in COX-2 immunoreactivity were restricted to dysplastic and neoplastic foci within intestinal mucosa.
CONCLUSIONS: These data show that COX-2 levels may be increased at an early stage in colorectal neoplasia during polyp formation and before invasion.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8831610     DOI: 10.1016/s0016-5085(96)70083-5

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  55 in total

1.  Synergistic induction of cyclooxygenase-2 by transforming growth factor-beta1 and epidermal growth factor inhibits apoptosis in epithelial cells.

Authors:  D Saha; P K Datta; H Sheng; J D Morrow; M Wada; H L Moses; R D Beauchamp
Journal:  Neoplasia       Date:  1999-12       Impact factor: 5.715

2.  Deletion of cytosolic phospholipase A(2) suppresses Apc(Min)-induced tumorigenesis.

Authors:  K H Hong; J C Bonventre; E O'Leary; J V Bonventre; E S Lander
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

3.  Selective visualization of cyclooxygenase-2 in inflammation and cancer by targeted fluorescent imaging agents.

Authors:  Md Jashim Uddin; Brenda C Crews; Anna L Blobaum; Philip J Kingsley; D Lee Gorden; J Oliver McIntyre; Lynn M Matrisian; Kotha Subbaramaiah; Andrew J Dannenberg; David W Piston; Lawrence J Marnett
Journal:  Cancer Res       Date:  2010-05-01       Impact factor: 12.701

Review 4.  Cyclooxygenase- and lipoxygenase-mediated DNA damage.

Authors:  N Speed; I A Blair
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

Review 5.  Cyclooxygenases and lipoxygenases in cancer.

Authors:  Claus Schneider; Ambra Pozzi
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

Review 6.  Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward.

Authors:  David G Menter; Richard L Schilsky; Raymond N DuBois
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531

Review 7.  Cyclooxygenase-2 and thromboxane synthase in non-endocrine and endocrine tumors: a review.

Authors:  Onder Onguru; Mary B Casey; Sabine Kajita; Nobuki Nakamura; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

8.  Concurrent suppression of hyperlipidemia and intestinal polyp formation by NO-1886, increasing lipoprotein lipase activity in Min mice.

Authors:  Naoko Niho; Michihiro Mutoh; Mami Takahashi; Kazuhiko Tsutsumi; Takashi Sugimura; Keiji Wakabayashi
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-14       Impact factor: 11.205

9.  Differential regulation of cyclooxygenase-2 in nontransformed and ras-transformed intestinal epithelial cells.

Authors:  Jianguo Du; Bo Jiang; John Barnard
Journal:  Neoplasia       Date:  2005-08       Impact factor: 5.715

10.  Reduction of intestinal neoplasia with adenomatous polyposis coli gene replacement and COX-2 inhibition is additive.

Authors:  John I Lew; Yuee Guo; Richard K Kim; Lisa Vargish; Fabrizio Michelassi; Richard B Arenas
Journal:  J Gastrointest Surg       Date:  2002 Jul-Aug       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.